Oslo, Norway, 22 June 2021

Reference is made to the stock exchange notice published on 18 June 2021, at
08:00 CEST, regarding a share capital increase in relation to current and former
board members' exercise of in total 51,966 RSUs.

In addition, current and former employees have exercised in total 58,400 share
options.

The issuance of 110,366 new shares has today been registered in the Norwegian
Register of Business Enterprises. Following registration, the share capital of
Nordic Nanovector ASA is NOK 19,615,676 divided into 98,078,380 shares, each
with a nominal value of NOK 0.20. Each share represents one vote in the
Company's general meeting.

For further information, please contact:

Malene Brondberg, CFO

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to the disclosure requirements in section 5-12 of
the Norwegian Securities Trading Act.